Thane (Maharashtra) [India], May 14: There is a version of a cancer diagnosis that most people know. You get the news. You start treatment. You hope it works. And if it does not, or if the cancer comes back, the options get fewer,and the conversations get harder.
Operating out of two dedicated hospitals in Thane and Khar, Mumbai, SunAct brings together some of the country's leading oncologists and haematologists under one roof. The hospital offers advanced cancer and blood disorder care, giving patients and families access to expert treatment, support, and hope closer to home.
The Doctors Behind It
SunAct was co-founded by two physicians who, between them, have spent decades working at institutions like Tata Memorial Centre and training at some of India’s most respected medical colleges.
Dr. (Prof.) Vijay Patil, co-founder and medical oncologist, has over two decades of clinical and research experience in solid tumours and next-generation cancer therapies. He has more than 750 peer-reviewed publications in journals like The Lancet Global Health and the Journal of Clinical Oncology.
Dr. Ashay Karpe, co-founder and haemato-oncologist, brings 23 years of experience focused on blood cancers, cellular therapies, and stem cell transplantation.
What SunAct Treats and How
SunAct offers a range of advanced cancer treatments across both its Mumbai facilities. Each of these is backed by specialist oversight, and each patient is individually evaluated before any treatment plan is finalised.
CAR-T Cell Therapy for Leukaemia and Blood Cancers
When leukaemia comes back after chemotherapy, families often feel like they have run out of road. CAR-T cell therapy for leukaemia in India at SunAct is one of the most significant treatments available for exactly these patients. It uses the patient’s own immune cells, reprogrammed to find and destroy the cancer cells that nothing else has been able to reach.
High-Dose IL-2 for Metastatic Kidney Cancer
Most treatments for metastatic kidney cancer are designed to slow things down. High-Dose Interleukin-2, which is a specialized immunotherapy, takes a different approach entirely. In select patients, it has produced complete, long-term remissions, not disease control, but actual remission lasting years without any ongoing therapy.
SunAct now offers HD IL-2 treatment for metastatic kidney cancer in India, with dedicated ICU-level monitoring and the specialist experience this treatment requires. Not every patient qualifies, and the team is clear about that from day one. But for those who do, the outcomes can be unlike anything else on offer.
Bone Marrow and Stem Cell Transplantation
Bone Marrow Transplantation (BMT) remains one of the most powerful treatments for certain oncology and hematological conditions. SunAct's transplant programme operates in a sterile, controlled environment built specifically for the complexity this procedure demands. Patients receive transplant care within the same centre, with the same team and without needing to move between facilities.
Immunotherapy
Immunotherapy at SunAct covers a broad range of treatments that work by helping the body’s own immune system fight cancer more effectively. For many patients across different cancer types, immunotherapy has changed what long-term outcomes look like. At SunAct, it is delivered with the same individual assessment and specialist review that applies to every treatment the centre offers.
Targeted Therapy
Targeted therapy works by identifying specific features of cancer cells and attacking those features directly, rather than broadly. The advantage is precision. For patients whose cancer has a specific genetic or molecular profile, targeted therapy often produces better results with fewer side effects than conventional treatment. SunAct’s oncology team assesses each patient’s profile and builds a plan around it.
Chemotherapy
Chemotherapy at SunAct is administered within the same specialist-led environment as everything else the centre does. Whether it is being used as a primary treatment or in combination with newer therapies, it is delivered with the same level of monitoring and care, in a facility designed around patient comfort and safety.
Paediatric & Adult Haematology, Oncology, and BMT
A diagnosis of a serious blood disorder or cancer can be overwhelming at any stage of life — for both patients and the families standing beside them. SunAct's Haematology, Oncology, and BMT programme is designed to provide specialised care for both children and adults, with treatment plans tailored to each patient's medical needs, overall health, and quality of life.
Why Families Choose SunAct
There are a few things that come up consistently when patients talk about why they came to SunAct, or why they stayed.
Everything in one place. Both centres in Mumbai are equipped for the full range of treatments SunAct offers. Patients are not being moved between hospitals or handed between care teams. The same specialists who assess a patient are the ones who treat them.
Access without having to leave India. Treatments like CAR-T therapy and HD IL-2 used to mean international travel for anyone serious about pursuing them. That is no longer the case. SunAct has built the infrastructure to deliver these therapies here, at a cost that does not require a patient to liquidate everything they have.
Honest conversations from the start. Not every patient who walks into SunAct is eligible for every treatment. The team is straightforward about that. If a newer therapy is not the right fit, the conversation moves to what is. The goal is always the best outcome for that specific patient, not a one-size-fits-all protocol.
A facility designed with purpose. SunAct’s isolation rooms, sterile environments, and monitoring setups are not general hospital infrastructure that has been adapted. They were built specifically for the kinds of most advanced treatments the centre delivers.
If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor